Myotwin

Executive Summary

Myotwin is a German biotechnology company leveraging a proprietary platform that combines human engineered heart tissues derived from induced pluripotent stem cells (iPSCs) with artificial intelligence to provide high-quality, multiparametric functional data for preclinical drug development. Founded in 2020 and headquartered in Munich, Myotwin addresses the critical need for more predictive models in cardiac drug discovery, aiming to de-risk and accelerate the development of therapies for heart disease and other conditions. By integrating lab-based tissue engineering with digital analysis, the platform offers insights into drug efficacy and toxicity beyond standard assays, potentially reducing late-stage failures and animal testing. The company operates on a service-based model, partnering with pharmaceutical and biotechnology firms to evaluate candidate drugs. As a preclinical-stage enterprise, Myotwin has not yet disclosed funding rounds, valuation, or commercial products, but its technology positions it within the growing field of organ-on-a-chip and AI-driven drug development. The company's success hinges on adoption by major pharma partners, validation through scientific publications, and securing Series A financing to scale operations and expand into other tissue types.

Upcoming Catalysts (preview)

• Q3 2026Pharmaceutical partnership for cardiac drug testing50% success
• Q2 2026Peer-reviewed publication validating platform performance70% success
• Q4 2026Series A funding round closing40% success